Scholarlink

Background <p>Clear cell renal cell carcinoma (ccRCC) lacks early clinical diagnostic markers, and advanced ccRCC has a poor prognosis. NSUN6, as a key component of m5C methyl-modifying enzymes, is abnormally expressed in several tumours and correlates with the prognosis. However, the expression and functional role of NSUN6 in ccRCC remain unknown.</p> Methods <p>NSUN6 expression was analysed using TCGA data, RT-qPCR, and Western blot. In vitro migration and invasion assays were used to assess the effect of NSUN6 on the malignant function of ccRCC cells. ssGSEA, ESTIMATE, CIBERDORT, and TIMER databases were used to study the immune cell infiltration of NSUN6 in ccRCC. TIDE database, IPS scores, and GDSC database were used to assess the different NSUN6-expressing groups’ drug therapeutic effects.</p> Results <p>Bioinformatics and clinical experiments demonstrated that the mRNA and protein expression of NSUN6 was significantly higher in ccRCC than in normal tissues. NSUN6 was an independent prognostic factor for ccRCC patients, and its high expression was significantly correlated with overall survival and disease-specific survival. In vitro experiments showed that NSUN6 promotes migration and invasion of ccRCC cells. NSUN6 was associated with immune infiltration of ccRCC and might affect the efficacy of immune and targeted therapies in patients.</p> Conclusion <p>High levels of NSUN6 were associated with poor prognosis in ccRCC and might promote tumour cell invasion and migration. In addition, NSUN6 played an important role in influencing the efficacy of tumour therapy. NSUN6 might further serve as a potential prognostic biomarker and therapeutic target.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

NSUN6 overexpression promotes malignant phenotypes and predicts poor prognosis in clear cell renal cell carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月9日

查看全文
  • Can Chen,
  • Shi-Yi Pan,
  • Jia Xu,
  • Xinyuan Cao,
  • Wei-Ming Zhang,
  • Hua-Guo Xu

摘要

Background

Clear cell renal cell carcinoma (ccRCC) lacks early clinical diagnostic markers, and advanced ccRCC has a poor prognosis. NSUN6, as a key component of m5C methyl-modifying enzymes, is abnormally expressed in several tumours and correlates with the prognosis. However, the expression and functional role of NSUN6 in ccRCC remain unknown.

Methods

NSUN6 expression was analysed using TCGA data, RT-qPCR, and Western blot. In vitro migration and invasion assays were used to assess the effect of NSUN6 on the malignant function of ccRCC cells. ssGSEA, ESTIMATE, CIBERDORT, and TIMER databases were used to study the immune cell infiltration of NSUN6 in ccRCC. TIDE database, IPS scores, and GDSC database were used to assess the different NSUN6-expressing groups’ drug therapeutic effects.

Results

Bioinformatics and clinical experiments demonstrated that the mRNA and protein expression of NSUN6 was significantly higher in ccRCC than in normal tissues. NSUN6 was an independent prognostic factor for ccRCC patients, and its high expression was significantly correlated with overall survival and disease-specific survival. In vitro experiments showed that NSUN6 promotes migration and invasion of ccRCC cells. NSUN6 was associated with immune infiltration of ccRCC and might affect the efficacy of immune and targeted therapies in patients.

Conclusion

High levels of NSUN6 were associated with poor prognosis in ccRCC and might promote tumour cell invasion and migration. In addition, NSUN6 played an important role in influencing the efficacy of tumour therapy. NSUN6 might further serve as a potential prognostic biomarker and therapeutic target.